Thanks for saving me a post at the swamp Max. You coulda said it was me that posted the post you copied from though.

Think all us real shareholders in in agreement that brilacidin will eventually be fully funded to move forward. And judging that the pace is starting to pick up, that may happen very soon. They could and I think probably would go to this EMA meeting with a full phase 3 protocol plan. Then at the meeting just tweak a few things. The inclusion/exclusion criteria for example. Patient numbers would be of great importance as well. A fully launched phase 3 running concurrently in the U.S. and throughout various locations in the EU, somewhere well over 100 patients imo.